AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Net Deferred Tax Liabilities by Year
Net Deferred Tax Liabilities ($M) ($M)
AbbVie Net Deferred Tax Liabilities: $3,715M in FY2025, up 21.9% from a year earlier.
Latest, FY2025
3,715
Period ended Dec 31, 2025
Change on a year earlier
+21.9%
3,047 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 14 Income Taxes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Deferred Tax Liabilities ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,715 | +21.9% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 3,047 | -19.9% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 3,803 | +358.2% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 830 | -212.9% | Form 10-K (filed 2024-02-20) ↗ |
| FY2021 | Dec 31, 2021 | -735 | – | Form 10-K (filed 2023-02-17) ↗ |
Cite this data
StockData. (2026). AbbVie Net Deferred Tax Liabilities ($M), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/dta-net-liab
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.